EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing

Fiona Clarke, Adelaide Grenfell, Sarah Chao, Helen Richards, Tony Korman, Benjamin Rogers iD

Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2896-2900

DOI: 10.1093/jac/dkae302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.09.2024. Verfasst von Fiona Clarke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Antifungal Agents, Echinocandins, Candidiasis, Ambulatory Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australia National Health & Medical Research Council Investigator Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outpatient parenteral antimicrobial therapy (OPAT) can deliver extended parenteral treatment of fungal infections in an ambulatory setting, whilst minimizing treatment burden and cost. The extended dosing interval of rezafungin may potentiate the benefits of OPAT.

Methods

This retrospective cohort study includes all adult patients who received echinocandin therapy in a large OPAT programme between 2012 and 2022. Patient characteristics, treatment and outcomes were studied. Data were analysed to determine the effects of replacing daily dosing with weekly dosing of echinocandin.

Results

Across the study period, 11% (44/386) of all patients in our Health Service treated with ≥7 days of echinocandin were managed via OPAT. All were Candida and related ‘yeast-like’ species infections. Nakaseomyces glabrata (20/41; 49%) was the most common pathogen, fungaemia the most common presentation (17/41; 41%) and azole resistance the most frequent indication for echinocandin use (21/41; 51%). In total, 633 days of echinocandin were administered as OPAT. Thirteen patients (13/41; 32%) received concurrent parenteral antibacterials. Treatment success was achieved in 30/41 (73%) patients. If daily echinocandin dosing was replaced with weekly dosing, a potential 52% (633 to 326) reduction in the total number of treatments (for any therapy) delivered by the OPAT team is possible. The ongoing need for daily antibacterial administration mitigated the benefit in some of this cohort.

Conclusions

Echinocandin therapy can be safely delivered via OPAT with outcomes equivalent to bed-based care. The extended dosing interval of rezafungin will allow for a substantial reduction in the number of treatments required across the patient cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsEchinocandinsCandidiasisAmbulatory CareHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTreatment OutcomeAdultCandidaOutpatientsAged, 80 and overDrug Administration Schedule

Substanzen

Antifungal AgentsEchinocandinsRezafungin

Autor:innen und Institutionen

  • Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
  • Monash Doctors, Monash Health, Clayton, Victoria, Australia.
  • Pharmacy Department, Monash Health, Clayton, Victoria, Australia.
  • Hospital in the Home, Monash Health, Clayton, Victoria, Australia.
  • Department of Microbiology, Monash Health, Clayton, Victoria, Australia.
  • Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health, Clayton, Victoria, Australia.

ORCID-Profile: Benjamin Rogers

Förderung

  • Australia National Health & Medical Research Council Investigator Grant

Zitieren

APA

Clarke, F., Grenfell, A., Chao, S., Richards, H., Korman, T., & Rogers, B. (2024). Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing. Journal of Antimicrobial Chemotherapy, 79(11), 2896-2900. https://doi.org/10.1093/jac/dkae302

Vancouver

Clarke F, Grenfell A, Chao S, Richards H, Korman T, Rogers B. Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing. Journal of Antimicrobial Chemotherapy. 2024;79(11):2896-2900. doi:10.1093/jac/dkae302

BibTeX
@article{Clarke2024,
  author = {Clarke, Fiona and Grenfell, Adelaide and Chao, Sarah and Richards, Helen and Korman, Tony and Rogers, Benjamin},
  title = {Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2896--2900},
  doi = {10.1093/jac/dkae302}
}
Kostenlos starten →